The Narcotic Analgesics Market is poised to grow inadvertently between 2021-2031. With infrastructure and technology vendors getting a hang of innovative technologies like big data, cloud, social media, and sensors, a major shift has occurred in conventional styles of production, storing, handling, and transportation of things. Thus, digital transportation ought to put the industry into digital trans in the upcoming period. This would be the trend going forward.
There has been increased attention on palliative care in the developing countries which also have increased reimbursements available for the same. All these factors are expected to drive the consumption of narcotic analgesics globally, thereby increasing the demand for this market.
Get Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/32866
In an article published by World Health Organization, on 4th August 2021, they estimated that approximately 62 million people used opioids in 2019. The number is expected to increase every year. The rising adoption and use of narcotic analgesics by the patients suffering from chronic pain is anticipated to propel the growth of this market in the future years.
There are various therapeutic applications of narcotic analgesics for the treatment of chronic pain associated with debilitating diseases like cancer and arthritis. Patients suffering from conditions which are associated with chronic pain usually develop a dependency on opioid-based drugs. This is another prominent factor that will pave the way for higher demand of narcotic analgesics in the forecast period.
The US center for Medicare and Medicaid services (CMS) on 1st January, 2019, implemented a new policy to prevent and combat opioid overuse along with limiting the prescription and dispensing of the narcotic analgesics.
With the introduction of various government initiatives and resolutions to control the addiction and abuse of opioids, which include the standardization of prescription for these drugs is creating ripples of transformation in the supply of narcotic analgesics globally.
Get A Customized Scope To Match Your Need Ask An Expert – sales@persistencemarketresearch.com
The FDA has approved these opioids in accordance with FDA industry guidelines, with labels describing abuse deterrent properties: Abuse Deterrent Opioides-Evaluation and Labeling:
- OxyContin
- Hysingla Er
- Xtampza Er
- RoxyBond
Post-operative care and palliative care reimbursements are driving demand for narcotic analgesics in the United States. The reimbursement scenarios for wound care and wound care have also led to a sharp increase in the consumption of narcotic analgesics.
It is expected that supporting insurance policies for chemotherapy cycles and post-operative care in developing countries will eventually drive the global demand for narcotic analgesics.
Request for Table of Content@ https://www.persistencemarketresearch.com/toc/32866
Around 20% of the adults in Europe suffer from some kind of moderate to severe chronic pain. The patients opt for narcotic analgesics for the management of such type of pain. This is expected to be a key factor in the growth of this field in the region.
- Purdue Pharma
- Pfizer Inc.
- Boehringer Ingelheim
- Janssen Pharmaceuticals Inc.
- Actavis Plc.
- Sanofi
- Mallinckrodt Pharmaceuticals
- Endo Pharmaceuticals Inc.
- Sun Pharmaceutical Industries Ltd
- Egalet
- Hikma Pharmaceuticals USA Inc.
- West-Ward Pharmaceuticals Corp.
- Vistapharm Inc.
- Glenmark Pharmaceuticals Inc.
- Blenheim Pharmacal Inc.
- SpecGx LLC
- Jamp Pharma Corporation
- Zyla Life Sciences US Inc.
- Ligand Pharmaceuticals Incorporated
- Astra Zeneca Lp
- Fresenius Kabi.
On 3rd March, 2020, FDA started to review the painkiller tanezumab, developed together by Pfizer and Eli, Lilly and Company, which is used for the treatment of chronic pain relief in patients suffering moderate to severe osteoarthritis, whose pain cannot be relieved by other analgesic drugs.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/32866
Key Segments:
By Product Type:
- Pentazocine
- Oxymorphone
- Morphine
- Hydromorphone
- Methadone
- Hydrocodone
- Fentanyl
- Oxycodone
By Drug type:
- Sustained-release Opioids (SROs)
- Immediate-release Opioids (IROs)
- Long-acting Opioids (LAOs)
By Form:
- Natural
- Semi-synthetic
- Synthetic
By Dosage Form:
- Tablets and Capsules
- Injections
- Films and Sprays
- Patches
- Oral Liquids
By Indication:
- Analgesia
- Surgical Pain
- Cancer Pain
- Neuropathic Pain
- Cough Suppression
- Diarrhea Suppression
By Distribution Channels:
- Hospital Pharmacies
- Retail Pharmacies
- Drug Stores
- Online pharmacies
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- MEA
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com
Website – https://www.persistencemarketresearch.com
1-2-1 Kinshi
Arca Central Building 14/F
Tokyo, 130-0013
Japan
18888633700